Education ▼

SPECIALTY TOPICS

CURRENTLY VIEWING
Chronic Lymphocytic Leukemia

Breast Cancer

Gastrointestinal Cancer

Colorectal Cancer

Ovarian Cancer

Prostate Cancer

Precision Medicine in Oncology^®

Neoadjuvant HER2+

More >>

Chronic Lymphocytic Leukemia

FDA Approval Sought for Ibrutinib/Rituximab in Frontline CLL/SLL

A supplemental new drug application has been submitted to the FDA for ibrutinib (Imbruvica) for use in combination with rituximab (Rituxan) for the first-line treatment of patients ≤70 years old with chronic lymphocytic leukemia or small lymphocytic...
Read More >>

Taking CLL Therapies From Bedside to Community

Ublituximab Plus Ibrutinib Improves PFS in Relapsed/Refractory High-Risk CLL

CLL Treatment Moves Toward Combo Approaches and CAR T-Cell Therapy

Rituximab Sets the Pace in Changing Lymphoma Landscape

Novel Agents, Combos Transforming Treatment in MCL and CLL

View More Stories >>

View Conference Coverage

2019 New York Lung Cancers Symposium

2019 Chemotherapy Foundation Symposium

2019 Hairy Cell Leukemia Foundation Annual Conference

2019 Lynn Sage Breast Cancer Symposium

2019 ESMO Congress

Dr. Al-Sawaf on Testing for CKT in CLL

Dr. Furman on Prognostic Markers in High-Risk CLL

Dr. Smith on PI3K Inhibitors in CLL

Dr. Wierda on the ASCEND Trial and BTK Inhibitor-Based Therapies in CLL

Dr. Smith on Frontline Treatment Considerations in CLL

Dr. Siddiqi on Rationale for the TRANSCEND CLL 004 Trial in CLL/SLL

Dr. Mato on Immunotherapy Options in CLL

OncLive houses thousands of videos that provide updates and information.
See more Videos

CLL: Practical Advice on Selecting and Managing Therapy

Acalabrutinib's Role in Treating Chronic Lymphocytic Leukemia

Venetoclax + Obinutuzumab: Impact on CLL Management

Frontline Therapy in CLL: Combination Strategies and MRD

Stratifying Patients With CLL to Frontline Therapy

Ibrutinib's Role as Frontline Therapy in CLL

OncLive houses thousands of videos that provide updates and information.
See more Videos

BTK Inhibitors in Chronic Lymphocytic Leukemia

Genomic Profiling in Chronic Lymphocytic Leukemia

Venetoclax-Based Regimens as First-Line Therapy in CLL

$Relapsed/Refractory CLL: Evaluating Other Novel Agents$

$Novel Approaches to Treating Relapsed/Refractory CLL$

$Continuing Therapy in Relapsed/Refractory CLL$

OncLive houses thousands of videos that provide updates and information.
See more Videos

Featured Programs

Other Promising Strategies in CLL

This expert panel discussion led by William Wierda, MD, focuses on promising strategies available for the treatment of chronic lymphocytic leukemia. Dr. Wierda is joined in this discussion by Steven Coutre, MD; Matthew S. Davids, MD, MMSc; Nicole Lamanna, MD; and Shuo Ma, MD, PhD.

View Now

The Use of Novel PI3K Inhibitors in CLL

In this segment William Wierda, MD, PhD, leads a panel discussion regarding the use of novel PI3K inhibitors in chronic lymphocytic leukemia.

View Now

Featured Video

Dr. Esteva on the Future of Biosimilars in Breast Cancer

Francisco J. Esteva, MD, PhD, director, breast medical oncology program, Laura and Isaac Perlmutter Cancer Center, NYU Langone Health, discusses the future use of biosimilars in breast cancer within the United States. View now

FDA Approval of a Biosimilar, Promising Data in Myeloma and GBM, and More